Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion

详细信息    查看全文

• 作者：Stephen A Gallo (1)
  Jacqueline D Reeves (2)
  Himanshu Garg (1)
  Brian Foley (3)
  Robert W Doms (2)
  Robert Blumenthal (1)
  
• 刊名：Retrovirology
• 出版年：2006
• 出版时间：December 2006
• 年：2006
• 卷：3
• 期：1
• 全文大小：1735KB
• 参考文献：1. Hahn BH, Shaw GM, De Cock KM, Sharp PM: AIDS as a zoonosis: scientific and public health implications. / Science 2000, 287: 607鈥?14. CrossRef
  2. Reeves JD, Doms RW: Human immunodeficiency virus type 2. / J Gen Virol 2002, 83: 1253鈥?265.
  3. Gallo SA, Sackett K, Rawat SS, Shai Y, Blumenthal R: The Stability of the Intact Envelope Glycoproteins is a Major Determinant of Sensitivity of HIV/SIV to Peptidic Fusion Inhibitors. / J Mol Biol 2004, 340: 9鈥?4. CrossRef
  4. Blumenthal R, Clague MJ, Durell SR, Epand RM: Membrane fusion. / Chem Rev 2003, 103: 53鈥?9. CrossRef
  5. Gustchina E, Hummer G, Bewley CA, Clore GM: Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV. / J Med Chem 2005, 48: 3036鈥?044. CrossRef
  6. Jernigan KM, Blumenthal R, Puri A: Varying effects of temperature, Ca(2+) and cytochalasin on fusion activity mediated by human immunodeficiency virus type 1 and type 2 glycoproteins. / FEBS Lett 2000, 474: 246鈥?51. CrossRef
  7. Puri A, Hug P, Munoz-Barroso I, Blumenthal R: Human erythrocyte glycolipids promote HIV-1 envelope glycoprotein-mediated fusion of CD4+ cells. / Biochem Biophys Res Commun 1998, 242: 219鈥?25. CrossRef
  8. Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, Rawat SS, Puri A, Durell S, Blumenthal R: The HIV Env-mediated fusion reaction. / Biochim Biophys Acta 2003, 1614: 36鈥?0. CrossRef
  9. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E, Doms RW: Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. / Proc Natl Acad Sci U S A 2002, 99: 16249鈥?6254. CrossRef
  10. Reeves JD, Miamidian JL, Biscone MJ, Lee FH, Ahmad N, Pierson TC, Doms RW: Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. / J Virol 2004, 78: 5476鈥?485. CrossRef
  11. Gallo SA, Puri A, Blumenthal R: HIV-1 gp41 Six-Helix Bundle Formation Occurs Rapidly after the Engagement of gp120 by CXCR4 in the HIV-1 Env-Mediated Fusion Process. / Biochemistry 2001, 40: 12231鈥?2236. CrossRef
  12. Chan DC, Kim PS: HIV entry and its inhibition. / Cell 1998, 93: 681鈥?84. CrossRef
  13. Furuta RA, Wild CT, Weng Y, Weiss CD: Capture of an early fusion-active conformation of HIV-1 gp41. / Nat Struct Biol 1998, 5: 276鈥?79. CrossRef
  14. Weissenhorn W, Dessen A, Calder LJ, Harrison SC, Skehel JJ, Wiley DC: Structural basis for membrane fusion by enveloped viruses. / Mol Membr Biol 1999, 16: 3鈥?. CrossRef
  15. Doms RW, Moore JP: HIV-1 membrane fusion: targets of opportunity. / J Cell Biol 2000, 151: F9鈥?4. CrossRef
  16. Sodroski JG: HIV-1 entry inhibitors in the side pocket. / Cell 1999, 99: 243鈥?46. CrossRef
  17. Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS: Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. / J Cell Biol 2000, 151: 413鈥?23. CrossRef
  18. Munoz-Barroso I, Durell S, Sakaguchi K, Appella E, Blumenthal R: Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. / J Cell Biol 1998, 140: 315鈥?23. CrossRef
  19. Salzwedel K, Berger EA: Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: Functional complementation of specific defects in gp120 and gp41. / Proceedings of the National Academy of Sciences 2000, 97: 12794鈥?2799. CrossRef
  20. Wyss S, Dimitrov AS, Baribaud F, Edwards TG, Blumenthal R, Hoxie JA: Regulation of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Fusion by a Membrane-Interactive Domain in the gp41 Cytoplasmic Tail. / J Virol 2005, 79: 12231鈥?2241. CrossRef
  21. Kim JT, Kim EM, Lee KH, Choi JE, Jhun BH, Kim JW: Leucine zipper domain of HIV-1 gp41 interacted specifically with alpha-catenin. / Biochem Biophys Res Commun 2002, 291: 1239鈥?244. CrossRef
  22. Tencza SB, Miller MA, Islam K, Mietzner TA, Montelaro RC: Effect of amino acid substitutions on calmodulin binding and cytolytic properties of the LLP-1 peptide segment of human immunodeficiency virus type 1 transmembrane protein. / J Virol 1995, 69: 5199鈥?202.
  23. Zhang H, Wang L, Kao S, Whitehead IP, Hart MJ, Liu B, Duus K, Burridge K, Der CJ, Su L: Functional interaction between the cytoplasmic leucine-zipper domain of HIV-1 gp41 and p115-RhoGEF. / Curr Biol 1999, 9: 1271鈥?274. CrossRef
  24. Evans DT, Tillman KC, Desrosiers RC: Envelope glycoprotein cytoplasmic domains from diverse lentiviruses interact with the prenylated Rab acceptor. / J Virol 2002, 76: 327鈥?37. CrossRef
  25. Wyss S, Berlioz-Torrent C, Boge M, Blot G, Honing S, Benarous R, Thali M: The highly conserved C-terminal dileucine motif in the cytosolic domain of the human immunodeficiency virus type 1 envelope glycoprotein is critical for its association with the AP-1 clathrin adaptor [correction of adapter]. / J Virol 2001, 75: 2982鈥?992. CrossRef
  26. Miller MA, Cloyd MW, Liebmann J, Rinaldo CR Jr, Islam KR, Wang SZ, Mietzner TA, Montelaro RC: Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein. / Virology 1993, 196: 89鈥?00. CrossRef
  27. Kliger Y, Shai Y: A leucine zipper-like sequence from the cytoplasmic tail of the HIV-1 envelope glycoprotein binds and perturbs lipid bilayers. / Biochemistry 1997, 36: 5157鈥?169. CrossRef
  28. Comardelle AM, Norris CH, Plymale DR, Gatti PJ, Choi B, Fermin CD, Haislip AM, Tencza SB, Mietzner TA, Montelaro RC, Garry RF: A synthetic peptide corresponding to the carboxy terminus of human immunodeficiency virus type 1 transmembrane glycoprotein induces alterations in the ionic permeability of Xenopus laevis oocytes. / AIDS Res Hum Retroviruses 1997, %20;13: 1525鈥?532. CrossRef
  29. Freed EO, Martin MA: Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. / J Virol 1996, 70: 341鈥?51.
  30. Wyma DJ, Kotov A, Aiken C: Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles. / J Virol 2000, 74: 9381鈥?387. CrossRef
  31. Wyma DJ, Jiang J, Shi J, Zhou J, Lineberger JE, Miller MD, Aiken C: Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail. / J Virol 2004, 78: 3429鈥?435. CrossRef
  32. Murakami T, Ablan S, Freed EO, Tanaka Y: Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity. / J Virol 2004, 78: 1026鈥?031. CrossRef
  33. Abrahamyan LG, Mkrtchyan SR, Binley J, Lu M, Melikyan GB, Cohen FS: The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle. / J Virol 2005, 79: 106鈥?15. CrossRef
  34. Edwards TG, Wyss S, Reeves JD, Zolla-Pazner S, Hoxie JA, Doms RW, Baribaud F: Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. / J Virol 2002, 76: 2683鈥?691. CrossRef
  35. Schols D, Struyf S, Van Damme J, Este JA, Henson G, De Clercq E: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. / J Exp Med 1997, 186: 1383鈥?388. CrossRef
  36. Sattentau QJ, Dalgleish AG, Weiss RA, Beverley PC: Epitopes of the CD4 antigen and HIV infection. / Science 1986, 234: 1120鈥?123. CrossRef
  37. Hoffman TL, LaBranche CC, Zhang W, Canziani G, Robinson J, Chaiken I, Hoxie JA, Doms RW: Stable exposure of the coreceptor-binding site in a CD4-independent HIV- 1 envelope protein. / Proc Natl Acad Sci U S A 1999, 96: 6359鈥?364. CrossRef
  38. Lin G, Baribaud F, Romano J, Doms RW, Hoxie JA: Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins. / J Virol 2003, 77: 931鈥?42. CrossRef
  39. Earl PL, Koenig S, Moss B: Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. / J Virol 1991, 65: 31鈥?1..
  40. Mulligan MJ, Ritter GD Jr, Chaikin MA, Yamshchikov GV, Kumar P, Hahn BH, Sweet RW, Compans RW: Human immunodeficiency virus type 2 envelope glycoprotein: differential CD4 interactions of soluble gp120 versus the assembled envelope complex. / Virology 1992, 187: 233鈥?41. CrossRef
  41. Chakrabarti S, Mizukami T, Franchini G, Moss B: Synthesis, oligomerization, and biological activity of the human immunodeficiency virus type 2 envelope glycoprotein expressed by a recombinant vaccinia virus. / Virology 1990, 178: 134鈥?42. CrossRef
  42. Reeves JD, Schulz TF: The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion. / J Virol 1997, 71: 1453鈥?465.
  43. Edinger AL, Blanpain C, Kunstman KJ, Wolinsky SM, Parmentier M, Doms RW: Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains. / J Virol 1999, 73: 4062鈥?073.
  
• 作者单位：Stephen A Gallo (1)
  Jacqueline D Reeves (2)
  Himanshu Garg (1)
  Brian Foley (3)
  Robert W Doms (2)
  Robert Blumenthal (1)
  
  1. Center for Cancer Research Nanobiology Program, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD, USA
  2. Dept. Microbiology, University of Pennsylvania, Philadelphia, PA, USA
  3. Los Alamos National Laboratories, Los Alamos, NM, USA
  
• ISSN：1742-4690

文摘

Background HIV envelope glycoprotein (Env)-mediated fusion is driven by the concerted coalescence of the HIV gp41 N-helical and C-helical regions, which results in the formation of 6 helix bundles. Kinetics of HIV Env-mediated fusion is an important determinant of sensitivity to entry inhibitors and antibodies. However, the parameters that govern the HIV Env fusion cascade have yet to be fully elucidated. We address this issue by comparing the kinetics HIV-1IIIB Env with those mediated by HIV-2 from two strains with different affinities for CD4 and CXCR4. Results HIV-1 and HIV-2 Env-mediated cell fusion occurred with half times of about 60 and 30 min, respectively. Binding experiments of soluble HIV gp120 proteins to CD4 and co-receptor did not correlate with the differences in kinetics of fusion mediated by the three different HIV Envs. However, escape from inhibition by reagents that block gp120-CD4 binding, CD4-induced CXCR4 binding and 6-helix bundle formation, respectively, indicated large difference between HIV-1 and HIV-2 envelope glycoproteins in their CD4-induced rates of engagement with CXCR4. Conclusion The HIV-2 Env proteins studied here exhibited a significantly reduced window of time between the engagement of gp120 with CD4 and exposure of the CXCR4 binding site on gp120 as compared with HIV-1IIIB Env. The efficiency with which HIV-2 Env undergoes this CD4-induced conformational change is the major cause of the relatively rapid rate of HIV-2 Env mediated-fusion.